Although insulin-like growth factor (IGF) binding protein-5 (IGFBP-5) is highly up-regulated in normal and malignant prostate tissues after androgen withdrawal, its functional role in castration-induced apoptosis and androgen-independent (AI) progression remains unde®ned. The objectives of this study were to characterise changes in IGFBP-5 expression following androgen ablation and during AI progression, evaluate the effects of changes in IGFBP-5 levels on IGF-1-mediated mitogenesis and AI progression, and test the effects of antisense IGFBP-5 oligodeoxynucleotide (ODN) on time to AI recurrence by using the androgen-dependent (AD) Shionogi and LNCaP tumour models.
Results
To analyse the functional signi®cance of these changes in IGFBP-5, human AD LNCaP prostate cancer cells were stably transfected with IGFBP-5 gene. Overexpression of IGFBP-5 stimulated LNCaP cell proliferation in both IGF-1-dependent and -independent manners, with corresponding increases in the fraction of cells in S G2/M phases of the cell cycle and P13K activity. Although treatment with a P13K inhibitor induced apoptosis in both control and IGFBP-5-overexpressing LNCaP cells, this P13K inhibitor-induced apoptosis was prevented by exogenous IGF-1 treatment only in IGFBP-5 transfectants, suggesting that high IGFBP5 levels potentiate the antiapoptotic effects of IGF-1. In vivo, IGFBP-5-overexpressing LNCaP tumours progressed signi®cantly faster to AI after castration compared to controls. In the Shionogi tumor model, IGFBP-5 expression increased b 100-fold within days after castration and remained elevated during AI progression. Treatment of Shionogi tumour cells in vitro with antisense IGFBP-5 ODN resulted in dose-dependent and sequence-speci®c decreases in IGFBP-5 mRNA and protein levels and signi®cant growth inhibition in a IGF-l-dependent manner, with corresponding decreased MAPK activity and S G2/M fraction. Systemic administration of antisense IGFBP-5 ODN in mice bearing Shionogi tumours after castration signi®cantly delayed time to progression to AI and inhibited growth of AI recurrent tumours.
Conclusion
Collectively, these data suggest that IGFBP-5 upregulation in prostate cancer cells after castration is an adaptive cell survival mechanism that helps potentiate the antiapoptotic and mitogenic effects of IGF-I, thereby accelerating progression to AI, and that use of antisense IGFBP-5 ODN to target IGF signal transduction is a potentially useful antiproliferative therapy that warrants further study.
